The use of piperacillin-tazobactam in neonatal and paediatric patients

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 1, 2009, Pages 57-69

  Wolf, Maria F ^a   Simon, Arne ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Children; Neutropenia; Nosocomial infection; Paediatric patients; Piperacillin tazobactam

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN TAZOBACTAM COMBINATION PRODUCT; PIPERACILLIN-TAZOBACTAM COMBINATION PRODUCT;

ABDOMINAL INFECTION; BACTERIAL COLONIZATION; CANCER PATIENT; CHILD; CYSTIC FIBROSIS; DRESS SYNDROME; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EMPIRICISM; ENTEROCOCCAL INFECTION; FEVER; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEADACHE; HEMOLYTIC ANEMIA; HOSPITAL INFECTION; HUMAN; INFANT; MALAISE; NEUTROPENIA; NEWBORN; NEWBORN INFECTION; PSEUDOMONAS INFECTION; PUSTULE; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; CLINICAL TRIAL; CROSS INFECTION;

NEGIBACTERIA;

ANTI-BACTERIAL AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HUMANS; INFANT, NEWBORN; PENICILLANIC ACID; PIPERACILLIN;

EID: 66449101863     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802614688     Document Type: Review

References (100)

1. Higashitani F, Hyodo A, Ishida N, et al. Inhibition of beta-lactamases by tazobactam and in vitro antibacterial activity of tazobactam combined with piperacillin. J Antimicrob Chemother 1990;25(4):567-574
2. No authors listed. FDA approved new drug bulletin: piperacillin/ tazobactam (zosyn), salmeterol xinafoate (serevent). RN 1994;57(8):49-52
3. Acar JF, Goldstein FW, Kitzis MD. Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993;31(Suppl A):23-28
4. Frank U, Mutter J, Schmidt-Eisenlohr E, Daschner FD. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clin Microbiol Infect 2003;9(11):1128-1132
5. Glasmacher A, Von Lilienfeld-Toal M, Schulte S, et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11(s5):17-23
6. Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007;5(3):365-383
7. Reed MD, Goldfarb J, Yamashita TS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994;38(12):2817-2826
8. Tornoe CW, Tworzyanski JJ, Imoisili MA, et al. Optimising piperacillin/tazobactam dosing in paediatrics. Int J Antimicrob Agents 2007;30(4):320-324
9. Berger A, Kretzer V, Apfalter P, et al. Safety evaluation of piperacillin/tazobactam in very low birth weight infants. J Chemother 2004;16(2):166-171
10. Flidel-Rimon O, Friedman S, Gradstein S, et al. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy. Acta Paediatr 2003;92(10):1205-1207
11. Flidel-Rimon O, Friedman S, Leibovitz E, Shinwell ES. The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data. Scand J Infect Dis 2006;38(1):36-42
12. Milisavljevic V, Wu F, Larson E, et al. Molecular epidemiology of Serratia marcescens outbreaks in two neonatal intensive care units. Infect Control Hosp Epidemiol 2004;25(9):719-721
13. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatol 1998;15(1):47-51
14. De Araujo OR, Da Silva DC, Diegues AR, et al. Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit. Braz J Infect Dis 2007;11(2):277-280
15. Millar M, Philpott A, Wilks M, et al. Colonization and persistence of antibiotic-resistant Enterobacteriaceae strains in infants nursed in two neonatal intensive care units in East London, United Kingdom. J Clin Microbiol 2008;46(2):560-567
16. Aoki M, Fukao T, Kaneko H, et al. Clinical and bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J Infect Chemother 2007;13(4):224-229
17. Tan L, Sun X, Zhu X, et al. Epidemiology of nosocomial pneumonia in infants after cardiac surgery. Chest 2004;125(2):410-417
18. Lidsky K, Hoyen C, Salvator A, et al. Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities. Clin Infect Dis 2002;34(6):760-766
19. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67(3):351-368
20. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006;12(6):428-432
21. Manno G, Cruciani M, Romano L, et al. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Int J Antimicrob Agents 2005;25(3):193-197
22. Nazik H, Ongen B, Erturan Z, Salcioglu M. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients. Jpn J Infect Dis 2007;60(2-3):82-86
23. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001;17(2):93-96
24. Canton R, Cobos N, De Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005;11(9):690-703
25. Arlicot N, Rochefort GY, Schlecht D, et al. Stability of antibiotics in portable pumps used for bronchial superinfection: guidelines for prescribers. Pediatrics 2007;120(6):1255-1259
26. Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002;46(8):2327-2332
27. Lambiase A, Raia V, Stefani S, et al. Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis. J Microbiol 2007;45(3):275-279
28. Caraher E, Reynolds G, Murphy P, et al. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur J Clin Microbiol Infect Dis 2007;26(3):213-216
29. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004;42(5):1915-1922
30. Hansen CR, Pressler T, Koch C, Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005;4(1):35-40
31. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-1756
32. Dzierzanowska-Fangrat K, Semczuk K, Lopaciuk U, et al. Antimicrobial susceptibility of aerobic microorganisms isolated from intraabdominal infections in pediatric patients in Poland. Med Sci Monit 2005;11(5):CR241-5
33. Arguedas A, Sifuentes-Osornio J, Loaiza C, et al. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. J Chemother 1996;8(2):130-136
34. Goldin AB, Sawin RS, Garrison MM, et al. Aminoglycoside-based triple-antibiotic therapy versus monotherapy for children with ruptured appendicitis. Pediatrics 2007;119(5):905-911
35. Maltezou HC, Nikolaidis P, Lebesii E, et al. Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2001;20(9):643-646
36. Nadler EP, Reblock KK, Ford HR, Gaines BA. Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children. Surg Infect (Larchmt) 2003;4(4):327-333
37. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006;12(3):212-216
38. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Bmj 2003;326(7399):1111
39. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57(2):176-189
40. Laws HJ, Ammann RA, Lehrnbecher T. Diagnostic procedures and management of fever in pediatric cancer patients. Klin Padiatr 2005;217(Suppl 1):9-16
41. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect 2006;12(7):606-620
42. Simon A, Groger N, Wilkesmann A, et al. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents 2006;28(5):417-422
43. Gaur AH, Flynn PM, Shenep JL. Optimum management of pediatric patients with fever and neutropenia. Indian J Pediatr 2004;71(9):825-835
44. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol 2006;23(3):177-186
45. Aksoylar S, Cetingul N, Kantar M, et al. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol 2004;21(2):115-123
46. Sato T, Kobayashi R, Yasuda K, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer 2008 [Epub ahead of print]
47. Yildirim I, Aytac S, Ceyhan M, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol 2008;25(4):291-299
48. Nurnberger W, Bonig H, Burdach S, Gobel U. Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation. Infection 1998;26(1):65-67
49. Simon A, Lehrnbecher T, Bode U, et al. Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2007;26(11):801-806
50. Wiesmayr S, Stelzmueller I, Mark W, et al. Experience with the use of piperacillin-tazobactam in pediatric non-renal solid organ transplantation. Pediatr Transplant 2007;11(1):38-48
51. Gavin PJ, Suseno MT, Thomson RB Jr, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006;50(6):2244-2247
52. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008;14(Suppl 1):181-184
53. Turner PJ. Extended-spectrum beta-lactamases. Clin Infect Dis 2005;41(Suppl 4):S273-5
54. Toltzis P. Antibiotic-resistant gram-negative bacteria in hospitalized children. Clin Lab Med 2004;24(2):363-380
55. Petros AJ, O'Connell M, Roberts C, et al. Systemic antibiotics fail to clear multidrug-resistant Klebsiella from a pediatric ICU. Chest 2001;119(3):862-866
56. Lee J, Pai H, Kim YK, et al. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 2007;60(3):629-637
57. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005;11(Suppl 6):10-17
58. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44(3):357-363
59. Agwu AL, Lee CK, Jain SK, et al. A World Wide Web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 2008;47(6):747-753
60. Harris AD, Kotetishvili M, Shurland S, et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 2007;35(2):97-101
61. Harris AD, Mc Gregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria? Clin Infect Dis 2006;43(Suppl 2):S57-61
62. Arndt PA, Garratty G, Hill J, et al. Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the 'immune complex' method. Vox Sang 2002;83(3):273-278
63. Grieco T, Cantisani C, Innocenzi D, et al. Acute generalized exanthematous pustulosis caused by piperacillin/tazobactam. J Am Acad Dermatol 2005;52(4):732-733
64. Maulidi H, Godambe S, Chow P. Suspected drug reaction with piperacillin/tazobactam, in a premature infant. Br J Clin Pharmacol 2008;65(6):971-972
65. Fahim S, Jain V, Victor G, Pierscianowski T. Piperacillin-tazobactam- induced drug hypersensitivity syndrome. Cutis 2006;77(6):353-357
66. Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf 2007;30(4):295-306
67. Reichardt P, Handrick W, Linke A, et al. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment- a retrospective analysis in 38 children with cystic fibrosis. Infection 1999;27(6):355-356
68. Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006;44(2):389-394
69. Penack O, Rempf P, Graf B, et al. False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam - is it still an issue? Diagn Microbiol Infect Dis 2008;60(1):117-120
70. Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004;42(10):4744-4748
71. Johnson DM, Biedenbach DJ, Jones RN. Potency and antimicrobial spectrum update for piperacillin/tazobactam 2000: emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002;43(1):49-60
72. Antoine TL, Curtis AB, Blumberg HM, et al. Knowledge, attitudes, and behaviors regarding piperacillin-tazobactam prescribing practices: results from a multicenter study. Infect Control Hosp Epidemiol 2006;27(11):1274-1277
73. Bradley JS. Antibiotic stewardship in pediatrics: a necessity. Pediatr Infect Dis J 2007;26(6):538-539
74. Zar HJ, Cotton MF. Nosocomial pneumonia in pediatric patients: practical problems and rational solutions. Paediatr Drugs 2002;4(2):73-83
75. Lehrnbecher T, Marshall D, Gao C, Chanock SJ. A second look at anorectal infections in cancer patients in a large cancer institute: the success of early intervention with antibiotics and surgery. Infection 2002;30(5):272-276
76. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002;34(11):1524-1529
77. Kennedy HF, Gemmell CG, Bagg J, et al. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother 2001;47(5):693-696
78. Huang WT, Chang LY, Hsueh PR, et al. Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients. J Microbiol Immunol Infect 2007;40(4):349-354
79. Fleischhack G, Schmidt-Niemann M, Wulff B, et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001;9(5):372-379
80. Bradley JS. Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr Infect Dis J 1997;16(3):263-268
81. Bradley JS, Faulkner KL, Klaugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996;15(8):749-757
82. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67(7):1027-1052
83. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother 2001;48(4):463-478
84. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med 2006;119(6 Suppl 1):S11-9; discussion S62-70
85. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342(10):710-721
86. Singh N, Leger MM, Campbell J, et al. Control of vancomycin-resistant enterococci in the neonatal intensive care unit. Infect Control Hosp Epidemiol 2005;26(7):646-649
87. Rice LB, Hutton-Thomas R, Lakticova V, et al. Beta-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 2004;189(6):1113-1118
88. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39(2):219-226
89. Winston LG, Charlebois ED, Pang S, et al. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control 2004;32(8):462-469
90. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23(5):1020-1025
91. Bradley SJ, Wilson AL, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43(2):261-266
92. Chavers LS, Moser SA, Funkhouser E, et al. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci. Microb Drug Resist 2003;9 (Suppl 1):S69-77
93. Mendez MN, Gibbs L, Jacobs RA, et al. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 2006;26(1):61-67
94. Paterson DL, Muto CA, Ndirangu M, et al. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008;52(2):465-469
95. Stiefel U, Paterson DL, Pultz NJ, et al. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect Control Hosp Epidemiol 2004;25(5):380-383
96. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341-5
97. Nourse C, Byrne C, Murphy H, et al. Eradication of vancomycin resistant Enterococcus faecium from a paediatric oncology unit and prevalence of colonization in hospitalized and community-based children. Epidemiol Infect 2000;124(1):53-59
98. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24(5):362-386
99. Hamidah A, Rizal AM, Nordiah AJ, Jamal R. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2008;49(1):26-30
100. Le Guyader N, Auvrignon A, Vu-Thien H, et al. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer 2004;12(10):720-724